But suppose a customer tests positive for one of the BRCA
Susan Domchek of the University of Pennsylvania's Basser Research Center for BRCA
, who also wasn't involved in the study.
The task force said that the new guideline reaffirms its 2005 recommendation on BRCA
testing, but noted that an update was in order because "the potential benefits and harms of medications for breast cancer risk reduction have been studied for longer follow-up periods, and Continued on following page more information is available about the potential psychological effects of genetic counseling and risk-reducing surgery"
The initial criteria for offering BRCA
testing were that the woman should be a proband affected by breast cancer with at least one additional risk factor on personal or family history.
Some 11 of 25 ovarian cancer patients with BRCA
mutations had a RECIST-positive response to treatment, as did seven of 18 breast cancer patients with BRCA
1/2 mutation carriers' perspectives on the "slippery slope" (Quinn et al., 2009) may exist in tension with each individual's experience of an illness that "runs in the family," as well as experiences of caregiving and loss (Brouwer-DudokdeWit, Savenije, Zoeteweij, Maat-Kievit, & Tibben, 2002; Chilibeck, Lock, & Sehdev, 2011; Hoskins, Roy, & Greene, 2012; Sobel & Cowan, 2003).
For example, women with a BRCA
mutation might have both breasts removed to prevent cancer from developing.
PROfound is a prospective, multi-center, randomised, open-label, Phase 3 trial evaluating the efficacy and safety of Lynparza versus enzalutamide or abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on prior treatment with a new hormonal anticancer treatment and have a qualifying tumor mutation in one of 15 genes involved in the homologous recombination repair pathway, among them BRCA
1/2, ATM and CDK12.
"The trial results to date have shown that olaparib maintenance therapy extends progression-free survival by around three years in women with BRCA
mutation linked advanced ovarian cancer.
"My book entitled, 'Understanding BRCA
' has just been released internationally and aims to improve the reader's understanding of the BRCA
gene, the biology of genetics and what it means if an individual carries a harmful mutation.
Interest in genetic testing for breast cancer predisposition surged following the actress Angelina Jolie's op-ed in the New York Times in May, 2013, revealing that she carried the BRCA
1 mutation and had undergone bilateral prophylactic mastectomy to reduce her breast cancer risk (1).